Citations

Mayo Clinic

Showing 10 of 108572 citations.

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Rosen, Lee S. , Algazi, Alain P. , Moser, Brian A., Hu, Tianle, Wang, Xuejing Aimee , Tuttle, Jay , Wooldridge, James E. , Banck, Michaela S., Banck, Michaela, Goldman, Jonathan W. , Turner, P. Kellie , Wacheck, Volker

Clinical Cancer Research | October 11, 2016 | Volume: 23 | Issue: 8 | Pages: 1910-1919

10.1158/1078-0432.ccr-16-1418 | PMID 27803065 Get It

Abstract Purpose: The MET/HGF pathway regulates cell proliferation and survival and is dysregulated in multiple tumors. Emibetuzumab (LY2875358) is a bivalent antibody that inhibits HGF-dependent and HGF-independent MET signaling. Here, we report dose escalation results from the first-in-human phase I trial of emibetuzumab. Experimental Design: The study comprised a 3+3 dose escalation for emibetuzumab monotherapy (Part A) and in combination with erlotinib (Part A2). Emibetuzumab was administered i.v. every 2 weeks (Q2W) using a flat dosing scheme. The primary objective was to determine a recommended phase II dose (RPTD) range; secondary endpoints included tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity. Results: Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non–small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. No dose-limiting toxicities and related serious or ≥ grade 3 adverse events were observed. The most common emibetuzumab-related adverse events included mild diarrhea, nausea, and vomiting, and mild to moderate fatigue, anorexia, and hypocalcemia in combination with erlotinib. Emibetuzumab showed linear PK at doses >210 mg. Three durable partial responses were observed, one for emibetuzumab (700 mg) and two for emibetuzumab + erlotinib (700 mg and 2,000 mg). Both of the responders to emibetuzumab + erlotinib had progressed to prior erlotinib and were positive for MET protein tumor expression. Conclusions: Based on tolerability, PK/PD analysis, and preliminary clinical activity, the RPTD range for emibetuzumab single agent and in combination with erlotinib is 700 to 2,000 mg i.v. Q2W. Clin Cancer Res; 23(8); 1910–9. ©2016 AACR.
Patient- and Provider-Centered Design of an Outpatient Diabetes Technology Clinic
Cramer, A , Scalzo, Patty , Bach, Sarah M., Kudva, Yogish C. , Cramer, Angela M, Bach, Sarah M.

Journal of Diabetes Science and Technology | October 11, 2016 | Volume: 11 | Issue: 3 | Pages: 499-505

10.1177/1932296816672690 | PMID 28745100 Get It

Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status
Hagen, Clint , Wiste, Heather J. , Mielke, Michelle M. , Roberts, Rosebud O., Vemuri, Prashanthi , Lowe, Val J. , Jack, Clifford R. , Petersen, Ronald C. , Machulda, Mary M. , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi

The Clinical Neuropsychologist | October 11, 2016 | Volume: 31 | Issue: 1 | Pages: 99-117

10.1080/13854046.2016.1241303 | PMID 27724156 Get It

Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration’s Approach for Its Product Labeling
Shrader, Peter, Thomas, Laine , Fonarow, Gregg C. , Kowey, Peter R. , Singer, Daniel E. , Ansell, Jack , Go, Alan S. , Piccini, Jonathan P. , Pokorney, Sean D, Pokorney, Sean D. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D.

Circulation | October 10, 2016 | Volume: 134 | Issue: 15 | Pages: 1122-1124

10.1161/circulationaha.116.024333 | PMID 27753615 Get It

Impact of a Preinterview Dinner on Candidate Perception of a Fellowship Training Program
Skalski, Joseph H. , Dulohery, Megan M., Kelm, Diana J. , Ramar, Kannan

Journal of Graduate Medical Education | October 10, 2016 | Volume: 8 | Issue: 5 | Pages: 763-766

10.4300/jgme-d-16-00162.1 | PMID 28018544 Get It

ABSTRACT Background The interview visit is an important component of residency and fellowship recruitment that requires a substantial expenditure of time and resources for both training programs and candidates. Objective Survey aimed to study the impact of a preinterview dinner on fellowship program candidates. Methods A single center preintervention and postintervention comparison study was conducted using an electronic survey distributed to all Pulmonary and Critical Care Fellowship candidates over 3 years (2013–2015). The interview visit in 2013 did not include a preinterview dinner (no-dinner group), while the candidates interviewing in 2014 and 2015 were invited to a preinterview dinner with current fellows on the evening before the interview day (dinner group). Results The survey was distributed to all candidates (N = 70) who interviewed between 2013 and 2015 with a 59% (n = 41) completion rate. Ninety percent of respondents (37 of 41) reported that a preinterview dinner is valuable, primarily to gain more information about the program and to meet current fellows. Among candidates who attended the dinner, 88% (23 of 26) reported the dinner improved their impression of the program. The dinner group was more likely to have a positive view of current fellows in the program as desirable peers compared to candidates in the no-dinner group. Conclusions This pilot study suggests that a preinterview dinner may offer benefits for candidates and training programs and may enhance candidates' perceptions of the fellowship program relative to other programs they are considering.
Low Testosterone in Men Should Be a Sign Rather Than a Number to Increase
Aktürk, Halis Kaan , Nippoldt, Todd B.

JAMA Internal Medicine | October 10, 2016 | Volume: 176 | Issue: 12 | Pages: 1743

10.1001/jamainternmed.2016.5761 | PMID 27723882 Get It

Editorial Comment
Tollefson, Matthew K.

Journal of Urology | October 8, 2016 | Volume: 197 | Issue: 1 | Pages: 82-82

10.1016/j.juro.2016.07.104 | PMID 27717688 Get It

Presentation and Management of Giant Fibrovascular Polyps of the Hypopharynx and Esophagus
Ongkasuwan, Julina , Anzalone, C. Lane , Salazar, Esperanza, Donovan, Donald T., Ongkasuwan, Julian

Annals of Otology, Rhinology & Laryngology | October 8, 2016 | Volume: 126 | Issue: 1 | Pages: 29-35

10.1177/0003489416672872 | PMID 27913720 Get It

Objective: Fibrovascular polyps of the hypopharynx and esophagus are rare, with few case reports in the literature. In this article, we present our institutional experience with a focus on airway and surgical management. Study Design: Case series. Setting: Tertiary academic institution. Methods: A retrospective review was conducted of 4 patients that presented to a tertiary medical center with fibrovascular polyps between 1990 and 2012. Patient demographics, clinical presentation, diagnostic studies, and surgical approaches were reviewed. A review of the published literature was also performed. Results: The average age at presentation was 72 years (range, 59-85 years). Among the 4 patients, 2 presented with airway compromise requiring tracheotomy. All patients had removal of the polyp shortly after presentation; 2 underwent transcervical approaches with lateral pharyngotomy/esophagotomy, and the other 2 had endoscopic removal. The polyps arose from the hypopharynx in 3 patients and upper esophagus in 1. Three patients had complete resolution of their symptoms and remained disease free. One patient had recurrence of the polyp 2 years later and is currently being observed. Conclusion: Fibrovascular polyps are rare tumors of the hypopharynx/esophagus that present in older adults. Although benign, they can cause life-threatening airway compromise that may necessitate tracheotomy. We present 4 cases of fibrovascular polyps and discuss our evolving surgical management, including endoscopic removal.
Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer
Kawakami, Hisato , Huang, Shengbing, Dutta, Shamit K., Pal, Krishnendu , Mukhopadhyay, Debabrata , Sinicrope, Frank A.

Molecular Cancer Therapeutics | October 8, 2016 | Volume: 15 | Issue: 12 | Pages: 3015-3027

10.1158/1535-7163.mct-16-0017 | PMID 27765849 Get It

Abstract Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated apoptosis resistance that occurs by an as yet undefined mechanism. We found that BRAFV600E can upregulate anti-apoptotic MCL-1 in a gene dose-dependent manner using colorectal cancer cell lines isogenic for BRAF. BRAFV600E-induced MCL-1 upregulation was confirmed by ectopic BRAFV600E expression that activated MEK/ERK signaling to phosphorylate (MCL-1Thr163) and stabilize MCL-1. Upregulation of MCL-1 was mediated by MEK/ERK shown by the ability of ERK siRNA to suppress MCL-1. Stabilization of MCL-1 by phosphorylation was shown by a phosphorylation-mimicking mutant and an unphosphorylated MCL-1 mutant that decreased or increased MCL-1 protein turnover, respectively. MEK/ERK inhibition by cobimetinib suppressed MCL-1 expression/phosphorylation and induced proapoptotic BIM to a greater extent than did vemurafenib in BRAFV600E cell lines. MCL-1 knockdown versus control shRNA significantly enhanced cobimetinib-induced apoptosis in vitro and in HT29 colon cancer xenografts. The small-molecule MCL-1 inhibitor, A-1210477, also enhanced cobimetinib-induced apoptosis in vitro that was due to disruption of the interaction of MCL-1 with proapoptotic BAK and BIM. Knockdown of BIM attenuated BAX, but not BAK, activation by cobimetinib plus A-1210477. In summary, BRAFV600E-mediated MEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonism combined with cobimetinib, suggesting a novel therapeutic strategy against BRAFV600E-mutant CRCs. Mol Cancer Ther; 15(12); 3015–27. ©2016 AACR.